| Bioactivity | KCA-1490 is a dual PDE3/4 inhibitor with IC50 values of 369 nM and 42 nM, respectively. KCA-1490 exhibits potent bronchodilatory and anti-inflammatory activity. KCA-1490 suppresses Histamine (HY-B1204)-induced bronchoconstriction in vivo, which is promising for research of asthma and chronic obstructive pulmonary disease (COPD)[1][2][3]. |
| CAS | 909719-71-7 |
| Formula | C14H13F3N4O2 |
| Molar Mass | 326.27 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ochiai K, et al. Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5833-8. [2]. Ochiai K, et al. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett. 2013 Jan 1;23(1):375-81. [3]. Jin J, et al. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes. Int J Mol Sci. 2023 Jul 15;24(14):11518. |
KCA-1490
CAS: 909719-71-7 F: C14H13F3N4O2 W: 326.27
KCA-1490 is a dual PDE3/4 inhibitor with IC50 values of 369 nM and 42 nM, respectively. KCA-1490 exhibits potent broncho
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.